CIP2A and chronic myelogenous leukemia, BCR-ABL1 positive: We have also shown that this antiapoptotic phenotype can be overcome in CML by targeting BCL-XL, thus identifying an effective therapeutic option for CML patients with high expression levels of CIP2A (Figure 7).